Blocklisting Interim Review
December 06 2010 - 2:00AM
UK Regulatory
TIDMMEDG
RNS Number : 3007X
Medgenics Inc
06 December 2010
Medgenics, Inc.
('Medgenics' or the 'Company')
Block Listing interim review
6 December 2010
1. Name of company:
Medgenics, Inc.
2. Name of scheme:
Warrants and Options under the Company's Share Incentive Schemes
3. Period of return: From
To
3 June 2010 3 December
2010
4. Number and class of securities not issued under the scheme at the beginning
of the period:
6,398,777 common shares of par value of US$0.0001 each ("Common Shares")
5. Number of securities issued under scheme during period:
431,232 Common Shares following the due exercise of Options issued by the
Company
6. Balance under scheme of securities not yet issued at end of period:
5,967,545 Common Shares
7. Number and class of securities originally admitted and the date of admission:
20,818,683 Common Shares admitted under the block admission on 4 December 2007.
Following the above issues during the period the total number of Common Shares
in issue is 180,586,438 .The percentage of shares not in public hands is 34.6
per cent.
For further information, contact:
Andrew Pearlman +972 4 902 8900
CEO
Medgenics, Inc
Mike Wort / Anna Dunphy +44 207 861 3838
De Facto Communications (PR)
James Pinner / Derek Crowhurst +44 207 444 0800
Religare Capital Markets (Nomad)
Ian Callaway / Alex Mattey +44 207 638 5600
SVS Securities plc (Joint Broker)
Jonathan Senior +44 207 776 1219
Nomura Code (Joint Broker)
+-------------------------------+-------------------------------+
| Leslie Wolf-Creutzfeldt | +1 646 284 9472 |
| Grayling (Investment | |
| Relations - US) | |
| | |
+-------------------------------+-------------------------------+
Notes to Editors:
Medgenics is a medical technology and therapeutics company focused on providing
sustained protein therapies, having developed its unique tissue-based Biopump
platform technology to provide sustained-action protein therapy for the
treatment of a range of chronic diseases. The first revenue generating
commercial deal with a well known multinational pharmaceutical company was
negotiated in late 2009 and we look forward to generating additional deals to
further commercialise the Biopump platform technology.
Biopumps are made using needle biopsies taken from the lower layer of the
patient's skin under local anaesthetic, and processed during 10-14 days to
become 30 mm long tissue biofactories producing the required protein. The
requisite numbers of Biopumps are injected under the patient's skin to provide
sustained protein production and delivery for several months. The Company is
developing the Biopump to provide substantially greater safety and reliability
in protein treatment in a more cost effective manner than experienced with the
existing injected protein therapies. Medgenics currently has three products in
development based on this technology, addressing the indications of:
- anaemia - using EPODURE, a Biopump producing erythropoietin (EPO)
- hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a)
- haemophilia - using a Biopump to produce clotting Factor VIII
The Company's Phase I/II clinical trial using EPODURE to treat anaemia in
patients with chronic kidney disease has demonstrated proof of concept of the
Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for
six months or more, EPODURE Biopumps have already provided anaemia treatment in
patients for 6 months or more, even at the low administered dose.
Medgenics intends to develop its innovative products and bring them to market
via multiple strategic partnerships with major pharmaceutical and/or medical
device companies. In addition to treatments for anaemia, hepatitis-C and
haemophilia, Medgenics plans to develop and/or out-license a pipeline of future
Biopump products targeting the large and rapidly growing global protein therapy
market, which is forecast to reach US $95 billion by the end of 2010. Other
potential applications of Biopumps producing various proteins include multiple
sclerosis, arthritis, paediatric growth hormone deficiency, obesity, and
diabetes.
CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, which include all statements
other than statements of historical fact, including (without limitation) those
regarding the Company's financial position, business strategy, plans and
objectives of management for future operations. These statements relate to
future events, prospects, developments and strategies. Forward-looking
statements are sometimes identified by their use of the terms and phrases such
as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning,
"expect," "believe," "will," "will likely," "should," "could," "would," "may" or
the negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and are subject to
risks and uncertainties. Should any of these risks or uncertainties materialize,
or should any of the Company's assumptions prove incorrect, actual results may
differ materially from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these forward-looking
statements, which speak only as of the date made. The Company expressly
disclaims any obligation or undertaking to disseminate any updates or revisions
to any forward-looking statements contained herein to reflect any change in the
Company's expectations with regard thereto or any change in events, conditions
or circumstances on which any such statements are based. As a result of these
factors, the events described in the forward-looking statements contained in
this release may not occur.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRTTBFTMBAMBIM
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024